PDS Biotech amends Phase 3 VERSATILE-003 trial to add PFS endpoint for potential accelerated approval of PDS0101

PDS Biotechnology Corp

Adopted protocol amendment for Phase 3 VERSATILE-003 trial adding progression-free survival as interim primary endpoint.
PFS endpoint supports potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer.
Median overall survival remains primary endpoint for full approval, per prior FDA Type C meeting.
FDA 30-day review period ended without objection; company proceeding with amended protocol.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.